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Abstract  
In a human intervention trial, a coffee, combining nature green coffee bean 
constituents and dark roast products was studied towards its potential to activate the 
Nrf2/ARE-pathway in PBLs. The study coffee was identified as a strong inducer of 
Nrf2 and downstream GST1A1 and UGT1A1 gene transcription. However, the 
response of the participants was found to depend on the respective genotype. The -
651 SNP in the Nrf2 gene as well as the heterozygote 6/7 sequence in the UGT1A1 
gene significantly down-regulated the susceptibility to respond to coffee, proposing 
the existing genotype to be critical for the response to the coffee.  
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Phase II enzymes play a critical role in converting reactive electrophiles or 
xenobiotics into less toxic products and seem to be crucial for cancer prevention. 
Thus, a deficiency in phase II enzyme activity has been associated with an increased 
risk of colon cancer [1, 2]. The expression of many phase II genes is regulated via 
the activation of antioxidant response elements (ARE) which are located in the 5’-
flanking region of their respective promoters. Activation by ROS or upstream protein 
kinases induce the translocation of the transcription factor Nrf2 (Nuclear factor-
erythroid 2 p45 subunit (NF-E2)-related factor 2 from the cytoplasm into the nucleus, 
its binding to ARE and the onset of the transcription of phase II enzymes such as 
glutathione S-transferases (GST), UDP-glucuronyl transferases (UGT) or γ-glutamyl 
cysteine ligase (γGCL) [3-12].  
Recently, we identified the typical dark roast coffee constituent N-methylpyridinium 
(NMP) as well as the green bean constituent n-chlorogenic acid (CGA) as potent 
activators of the Nrf2/ARE pathway [13].  
Four weeks consumption of a coffee blend combining both, typical dark roast 
characteristics as NMP with considerable amounts of green bean constituents 
significantly increased mean Nrf2 gene transcripts in peripheral blood lymphocytes 
(PBLs) of the participants of a human intervention trial [14, 15]. Yet, large differences 
in the Nrf2 activation ability were detected amongst the individuals, which could not 
be explained by the differences in the general health status or in the nutritional 
behavior of the participants.  
It has previously been reported that genetic variations in certain antioxidative genes 
critically determine their capability to be activated by bioactive food compounds [16]. 
Biochemical studies have associated allelic variations in the Nrf2 promoter region 
with differences in the ability to increase antioxidative phase II gene transcription [17]. 
To date, 9 Single Nucleotide Polymorphisms (SNP) have been identified in the Nrf2 
gene [17-19]. Of special relevance seems to be the -617C/A polymorphism and the -
651G/A SNP, which are located in the promoter region of the gene. Both SNPs were 
found to reduce the transcriptional activity of Nrf2, reflected by extenuated binding of 
Nrf2 to the ARE, resulting in decreased Nrf2-dependent gene transcription [17]. 
Genotyping of a subset of the study collective of HSII hinted at a connection between 
the respective Nrf2 genotype and the response to coffee [15].  
Based on these findings aim of the current intervention trial was (a) to test the Nrf2-
activation potential of the study coffee in a larger cohort and (b) to comprise whether 
the individual differences in the response to the study coffee is associated with the 
presence of different genotypes of Nrf2, GST1A1 and UGT1A1 genes. 
Results  
Nrf2 genotype and gene transcription 
A 424 bp polymorphic region of the Nrf2 promotor was sequenced in all participants 
of the intervention trial to detect the -617C/A, the -653A/G and the -651G/A 
polymorphisms which have already been discussed to be functionally relevant for the 
transcriptional activity of the Nrf2 gene [17]. 
The -617C/A SNP was present in 10/49 (20 %) of the participants (Tab. 1). The 
presence of the -651G/A SNP was observed in 15/49 individuals (31 %) and 31/49 
(63 %) of the participants possessed a SNP at position -653A/G. Changes in Nrf2 
gene transcription were assessed at the different blood collection points (CPs) in the 
course of the study. A potent induction of Nrf2 gene transcription after four weeks 
consumption of the study coffee (BC3) in comparison to both, wash out (BC2) as well 
as normal diet (BC1) was detected (Fig.1A). Thus, 65 % (32/49) of all participants 
displayed a ≥1.5 induction of gene transcription after coffee consumption.  
On closer examination of the genotype-dependent magnitude of the Nrf2 activation, -
651 SNP carriers displayed a weaker Nrf2 activation after coffee consumption (BC3) 
than carriers of the WT or any other SNP (Fig. 1B). Comparing the sensitivity of the 
response between all occurring genotypes displayed that individuals carrying the -
617 and the -651 SNP concomitantly possessed the lowest potential to activate Nrf2 
gene transcription (data not shown). 
GST1A1 genotype and gene transcription 
An already know polymorphism in the GST1A1 gene which consists of two alleles, 
GST1A1∗A and GST1A1∗B was monitored [20]. The two genotypes differ in three 
linked base changes in the 5’-regulatory region of the gene (a T/G change at −567, a 
C/T change at −69 and G/A change at −52). Presence of C/T base change at 
position -69 (GST1A1*B) gave rise to a EAR1 restriction enzyme cutting site, 
resulting in two fragments of length 380 bp and 100 bp whereas GST1A1*A 
homozygotes show only one band at 480 bp (data not shown). 
From the participants of the intervention trial, 24/48 (50 %) were found to carry an 
A/A genotype, 18/48 (38 %) the heterozygote A/B genotype and 6/48 (12 %) the 
more rarely homozygote B/B genotype (Tab. 1). To investigate whether four weeks 
intervention with the study coffee modulates GST1A1 transcription levels, as an 
important member of the antioxidative GST enzyme family, changes in gene 
transcription were determined during the course of the trial. GST1A1 gene 
transcription was potently elevated in the mean of the participants after four weeks 
consumption of coffee (BC3) in comparison to wash out (BC2, Fig. 2A). Separation of 
the participants with respect to their response to coffee resulted in 54 % of the 
participants displaying ≥1.5 induction of GST1A1 gene transcription after coffee 
consumption. Furthermore, this group of coffee responders displayed a higher 
induction of Nrf2 gene transcription following their individual normal diet (BC1). 
Subsequently, the GST1A1 genotype was correlated to the changes in GST1A1 
gene transcription during the course of the trial. No significant difference in the 
magnitude of GST1A1 activation was apparent in relation to the GST1A1 genotype. 
However, individuals possessing the BB homozygote genotype seemed to be slightly 
more susceptible to coffee consumption (data not shown).  
The GST1A1 gene carries an ARE sequence in its promotor region, hence it 
transcription is activated by Nrf2. Transcriptional activity of Nrf2, and thus the ability 
to activate ARE-dependent genes seems to depend on the Nrf2 genotype of the 
individual. An Nrf2 genotype-dependent magnitude of GST1A1 activation was 
detected for the study collective. Participants carrying the -651SNP, accounting to 31 
% of the participants showed no increase in GST1A1 gene transcription after coffee 
consumption (Fig. 2B). Thus, the Nrf2 genotype seems to be critical for GST1A1 
response. 
UGT1A1 represents a further important phase II gene in cellular detoxification 
processes. The activation of UGT1A1 gene transcription in mice by coffee has 
already been reported [21]. Thus, studies on changes of UGT1A1 gene transcription 
in the participants of the intervention trial were included. UGT1A1 possesses a 
known variation in its promotor sequence [22]. Moreover, the presence of such an 
additional TA repeat in the TATA region of the UGT1A1 promoter (7 TA repeats; 
UGT1A1*28) markedly decreases UGT1A1 expression and leads to a reduced 
sensitivity of the gene [22, 23]. Most participants of the present intervention trial were 
found to possess either a homozygote [TA]6/6-repeat sequence (wild type, 21/46 
individuals (46 %)) or were heterozygote ([TA]6/7 (19/46 individuals (41 %)), whereas 
only 13 % (6/46) of the individuals could be identified as homozygote [TA]7/7-repeat 
sequence carriers (Tab. 1).  
A strong variation in UGT1A1 gene transcription levels amongst the participants was 
detected at the beginning of the trial (BC1, Fig. 3A), whereas the response to coffee 
seemed to be more distinct (BC3). In average an induction of UGT1A1 gene 
transcription was observed after four weeks intervention with the study coffee. 
Furthermore, the absence of the coffee (second wash out period, BC4) resulted in a 
down-regulation to base level, emphasizing coffee to be crucial for the strong 
induction at BC3. By separation of the participants into groups of responders (BC3 
≥1.5) and non-responders (BC3 <1.5), 63 % of the individuals could be identified as 
coffee responders, not only supporting former findings, that coffee activates UGT1A1 
gene transcription but even showing this in humans (Fig. 3A).   
The changes in UGT1A1 transcription during the trial were correlated to the UGT1A1 
genotype with special emphasis to the response to the coffee intervention period, 
demonstrating a significant correlation between a reduced response to coffee and the 
presence of the 6/7 heterozygote genotype (Fig. 3B). Individuals carrying either a 6/6 
homozygote or a 7/7 heterozygote genotype responded equally sensitive to coffee. 
Correlating the response in UGT1A1 gene transcription to the Nrf2 genotype 
indicated the -651 Nrf2 genotype to be less accessible to coffee-mediated onset of 
gene transcription. Individuals, carrying the -651 Nrf2 genotype showed no increase 
in UGT1A1 gene transcription after coffee consumption (BC3) in comparison to wash 
out (BC2) whereas individuals, carrying the WT, -617SNP or the -653SNP displayed 
a potent onset of UGT1A1 gene transcription after coffee consumption (Fig. 3C). 
Linking the presence of the less sensitive responding 6/7 heterozygote UGT1A1 
genotype to the less sensitive -651 Nrf2 genotype displayed that 63 % (5/8) of 
individuals carrying both, the 6/7 UGT1A1 and the -651 Nrf2 genotype at the same 
time belonged to the group of coffee non-responders hinting at a strong correlation 
between the genetic background of the individuals and their response to coffee. 
 
Discussion  
The study coffee was identified as potent inducer of the antioxidative and 
chemopreventive Nrf2/ARE pathway in humans, as exemplified by a significant 
increase in Nrf2, GST1A1 and UGT1A1 gene transcription after four weeks 
consumption in the mean of the 51 participants, but yet with large differences in the 
individual response to the study coffee (Fig. 1A, 2A, 3A). Having a closer look on the 
particular response of the participants revealed for each gene a larger group of 
responders (Nrf2 65 % (32/49); GST1A1 54 % (26/48) and UGT1A1 63 % (29/46)) 
showing ≥1.5 fold increase in gene transcription after coffee intervention (BC3) in 
comparison to the previous wash out period (BC2) as well as a smaller group of non-
responders (Nrf2 35 % (17/49); GST1A1 46 % (22/48) and UGT1A1 37 % (17/46)) 
with <1.5 fold increase in gene transcription after coffee consumption. However, 
these variations could neither be explained by differences in the uptake of any 
antioxidative food/ food stuff despite coffee or gender, ethnicity or age. To elucidate, 
whether the presence of a particular genotype might influence the response to 
coffee, regions within the Nrf2, GST1A1 and UGT1A1 gene, carrying know 
polymorphisms already associated to affect the transcriptional activity of the genes 
were determined [15, 17, 20, 22, 23].  
The ratio of most occurring Nrf2 SNPs matches available literature data (Table 1). 
The -617C/A SNP was present in 10/49 (20 %) of the participants. The frequency of 
the -651G/A SNP was observed in 15/49 individuals (31 %) and 31/49 (63 %) of the 
participants displayed a SNP at position -653A/G. Thus, the study collective reflected 
the highest presence of the -653 SNP in the Nrf2 promotor. This is in line with 
previously published data [15], however higher than data published by Marzec et al. 
(2007). Taking into account that the study collective of Marzec et al. (2007) 
comprised 20 individuals, numbers of the present study (51 individuals) and 
previously published data (18 individuals) can be stated as more powerful. Thus, a 
presence of the -653 SNP of 56-63 % in Caucasians seems to be likely.  
Moreover, a polymorphism in the GST1A1 gene which consists of the two alleles 
GST1A1∗A and GST1A1∗B was examined [21]. As given in Table 1, 24/48 (50 %) of 
the participants were identified as A/A carriers, 18/48 (38 %) possessed the 
heterozygote A/B genotype and 6/48 (12 %) were B/B carriers. The frequency of the 
different GST1A1 genotypes is comparable to former findings in Caucasians [20] 
indicating that the study collective seems to represent an average population profile.  
The UGT1A1 gene possesses the known variation UGT1A1*28, which varies among 
ethnicities, being highest in those of African (43 %) or European (54 %) descent and 
lowest in those of Asian (16 %) descent [23].The study collective displayed a ratio 
within the expected range (Table 1). Hence 21/46 individuals (46 %) possessed the 
wild type sequence ([TA]6/6-repeat) and 19/46 participants (41 %) a heterozygote 
genotype ([TA]6/7-repeat). 6/46 individuals (13 %) carried a homozygote [TA]7/7-repeat 
sequence. However, the low presence of this genotype is also supported by literature 
data [23]. 
Linking the changes in gene transcription of Nrf2, GST1A1 and UGT1A1 during the 
course of the two month trial to the respective genotypes displayed several 
associations. Apparently a genotype-dependent response to coffee was observed for 
the -651 SNP of Nrf2. Individuals, carrying this genotype showed a considerably 
lower magnitude of induction in Nrf2 gene transcription during the coffee intervention 
period (BC3) than participants carrying the WT sequence, a -617 or -653 SNP (Fig. 
1B).  
UGT1A1 gene transcription was significantly up-regulated in most (63 %) of the 
participants of the present intervention trial. The UGT1A1 gene also reflected the 
strongest variation in the response to the study coffee in association to the present 
genotype. Both, the magnitude of the response, as well as the frequency of induced 
UGT1A1 gene transcription after coffee consumption was significantly decreased in 
carriers possessing a heterozygote 6/7 sequence in the determined promotor region. 
18/51 (35 %) of the individuals carried this genetic modification and most of this 
individuals failed to show an increased UGT1A1 gene transcription after coffee 
consumption (Fig.3B). 
Different authors reported a reduced Nrf2 transcriptional activity in individuals 
carrying genetic variations in the Nrf2 promotor region [17, 18], with effects on 
downstream ARE-dependent gene transcription. In the present study, individuals 
carrying the SNP at -651 in the Nrf2 gene reflected a significantly reduced response 
to coffee, apparent in a significantly lower induction of Nrf2-dependent GST1A1 and 
UGT1A1 gene transcription (Fig. 2B, 3C). These findings are supported by Marzec et 
al. (2007) who detected a reduced transcriptional activity of Nrf2, reflected by an 
extenuated binding of Nrf2 to the ARE (EpRE) in the presence of the -651 SNP. 
Furthermore, individuals carrying this genetic variation seem to suffer more frequently 
from acute lung injury (ALI), a disease, related to a reduced antioxidative cell defence 
[17]. However, his findings explained the influence of the genotype on general/ 
physiological gene transcription, whereas the effects on the transcriptional activation 
after food intervention were investigated, here.  
 
Taken together, the study coffee, combining potent Nrf2 inducers from green coffee 
beans with typical high roasted constituents could be identified as a potent inducer of 
antioxidative cell protection in the mean of the participants of the two month coffee 
intervention trial. Differences in the response to the coffee within the study collective, 
resulting in a group of responders and non-responders for the transcription of Nrf2, 
GST1A1, UGT1A1 in peripheral blood lymphocytes could be associated, an effect, 
which seems to occur in most human intervention trial. The occurrence of the -651 
SNP in the Nrf2 gene as well as the presence of a heterozygote 6/7 sequence in the 
downstream Nrf2-dependent phase II gene UGT1A1 potently down-regulated the 
susceptibility to respond to coffee with an increase in antioxidative gene transcription. 
We therefore suggest the genotype to be considered as important background 
criteria to evaluate the outcome in human intervention trials, targeting Nrf2-
dependent gene response and thus, to estimate the chemopreventive potency of 
bioactive food/ food constituents. 
 
Methods 
Coffee brew 
The study coffee brew consisted of a special roasted and blended Arabica coffee, 
characterized by a high concentration of both, green and roasted bean constituents, 
especially n-chlorogenic acid (252 mg/L) and NMP (76 mg/L). The caffeine level 
(720 mg/L) was in an average range of conventional coffee brews. The ground coffee 
was delivered in vacuum bags, each containing a filter pad of 12.5 g study coffee. 
Immediately before consumption, the coffee brew was freshly prepared by a Senseo 
coffee maker (Philips) by putting two pads into the large strainer and pushing the 
“two-cup” button. Each individual consumed 250 mL (three times a day). 
 
Subjects 
The study was approved by the Griffith University Human Research Ethics 
Committee (EC00162). The final test population was comprised of 25 male and 26 
female (total n = 51) healthy non-smoking (age 18-61, BMI 19-38) Caucasians. 
Originally, 57 individuals were recruited, however 6 individuals dropped out because 
of several reasons (change in living situation: moving away, new job situation and 
incompatibilities (gastric symptoms or sleeplessness after coffee consumption). All 
participants had to be regular coffee drinkers (2-6 cups of coffee/d). Participants were 
asked to maintain their usual dietary habits for the duration of the study, except for 
the intake of coffee, caffeinated products, dietary supplements and foods rich in 
polyphenols. All volunteers were informed of the objectives of the study and consent 
received for their participation. Exclusion criteria were smoking and use of 
medication. Furthermore, competitive athlete could not apply. The 8 week 
intervention trial was designed as follows: week 1+2, 1st wash out; week 3-6, coffee 
consumption and week 7+8, 2nd wash out. The participants consumed 750 mL of 
freshly brewed coffee (with/without sugar, addition of milk up to 50 mL) in three equal 
portions (morning, noontime, afternoon). In the wash out periods, the coffee brew 
was replaced by equal volumes of water. Nutritional reports during a 7-day periods 
were completed by the participants in the last week of each study period. Urine/blood 
sampling was performed at the beginning of the study and at the last day of each 
study period in the morning, after a fasting period of at least 6 hours in advance.  
Genomic DNA isolation 
For genomic DNA (gDNA) isolation, the QIAamp DNA Mini kit (QIAGEN) was applied 
and gDNA was purified as per the manufacturer’s instructions. Briefly, 20 μl of 
proteinase K were pipetted into the bottom of a 1.5 mL tube and 200 μL of whole 
blood were added. Thereafter, 200 μL of Buffer AL were added and vortexed for 15 s. 
After incubation at 56 °C for 10 min and brief centrifugation, 200 μL of ethanol (96 %) 
were added and again mixed by vortexing for 15 s. The mixture was then applied to a 
spin column and centrifuged at 6000 x for 1 min. Subsequently, the spin column was 
placed in a clean 2 ml collection tube (the filtrate was discarded). 500 μL of Buffer 
AW1 were added onto the spin column and centrifuged at 6000 x g for 1 min. 
Thereafter, the spin column was placed in a clean 2 ml collection tube (the filtrate 
was discarded), 500 μL Buffer AW2 were added and centrifuged at full speed for 3 
min. Subsequently, the spin column was placed in a clean 1.5 mL tube and 200 μL 
H2O dest. was added. After 1 min incubation at RT a centrifugation step at 6000 x g 
for 1 min, the final concentration of DNA was quantified using a ND-1000 
spectrophotometer (Nanodrop, Delaware). 
Sequencing 
SNPs rs35652124, rs6706649 and rs6721961: 
To obtain the 424 bp polymorphic region of the NFE2L2 gene, 80 ng of gDNA was 
amplified with 4 µL of GoTaq® Flexi buffer (Promega), 2.5 mM MgCl2, 0.2 mM dNTP, 
0.2 µM of each NFE2L2 primer (forward primer 5’–GACCACTCTCCGACCTAAAGG–
3’ and reverse primer 5’–CGAGATAAAGAGTTGTTTGCGAA-3’) and 0.2 µL GoTaq® 
to a total reaction volume of 20 µL. Amplification was performed on a VeritiTM 96-well 
Thermal Cycler (Applied Biosystems) with an initial step of 94 °C for 10 min, followed 
by 30 cycles of 94 °C for 45 sec, 55 °C for 45 sec and 72 °C for 45 s followed by a 
final extension of 72 °C for 7 min. Following amplification, 5 µL of PCR product was 
electrophoresed on 2% agarose gels stained with ethidium bromide for 30 min at 80 
V. PCR products were purified with the ExoSAP-IT® PCR cleanup kit 
(Affymetrix/USB) according to the manufacturer’s instructions. Briefly, 5 µL of PCR 
product, 1 µL of Exo SAP-IT® and 4 µL dH2O were carefully mixed prior to incubation 
at 37 °C for 15min, followed by incubations at 80 °C for 15 min and 4 °C for 3 min. 
DNA concentration was quantified using a ND-1000 spectrophotometer (Nanodrop, 
Delaware) and diluted to a concentration of 20 ng/µL DNA. For the sequencing 
reaction 1 µL of this DNA was added to 5 µL of BigDye Terminator v3 (BDT v3.1, 
Applied Biosystems), 1.3 µL of each NFE2L2 primer (one forward and one reverse 
reaction), 3.0 µL of 5 x BDT v3.1 Sequencing buffer to a final volume of 20uL. 
Amplification cycles were as follows: 96 °C for 1 min, followed by 30 cycles of 96 °C 
for 10 sec, 50 °C for 5 sec and 60 °C for 4 min followed by 4 °C for 5 min, 10 °C for 5 
min and 4 °C for 2min. The sequencing reaction product was transferred to a 1.5 ml 
eppendorf tube and ethanol precipitated by adding 2 µL of iced cold 3M sodium 
acetate (pH 5.2) and 2 µL of 125 mM EDTA (pH 8.0). After adding the sequencing 
reaction product the sample was vortexed briefly, centrifuged at 10,000 g for 5 
minutes, followed by addition of 50 µL of 100% ethanol followed by repeated 
vortexing and re-spinning the samples at 10,000 g for 5 minutes. Samples were then 
incubated for 15 min at RT. The product was then precipitated by centrifugation at 
10,000 x g followed by incubation at 4 °C for 20 min. The supernatant was removed 
and the pellet rinsed in 70% ethanol, briefly vortexed and centrifuged again at 10,000 
x g at 4 °C for 5 min. The pellet was completely dried using a DNA Speed Vac® 
(Savant) on high drying mode for 5 min. Samples were then resuspended in 15 µL 
dH2O. The purified products were then either stored at -20 °C or directly added into a 
Micro AmpTM optical 96 well reaction plate (Applied Biosystems) to be analyzed on a 
3130 genetic analyzer (Applied Biosystems).  
GST1A1 genotyping 
GST1A1 genotyping was carried out with Restriction Fragment Length Polymorphism 
(RFLP). First, PCR amplification was done. Gene-specific primers (forward primer 5’-
TGTTGATTGTTTGCCTGAAATT-3’; reverse primer 5’-
GTTAACGCTGTCACCGTCCT-3’) ’were used to generate a 480 bp PCR product 
spanning the site containing the polymorphism. For the amplification of GSTA1 40 ng 
of gDNA was amplified with 4 µL of GoTag® Flexi buffer (Promega), 2.5 mM MgCl2, 
0.2 mM each dNTP, 0.1 µM of each GST1A1 primer and 1 U Taq polymerase was 
added to a total reaction volume of 20 µL. Amplification was performed on a VeritiTM 
96-well Thermal Cycler (Applied Biosystems) with an initial denaturation of 94 °C for 
10 min, followed by 30 cycles of 94 °C for 45 s, 58 °C for 45 s and 72 °C for 45 s, 
followed by a final extension of 72 °C for 7 min. Following amplification, PCR 
products were electrophoresed on 2% agarose gels stained with ethidium bromide for 
30 min at 80 V. A no template control was included to detect possible contamination 
issues. This PCR product was then digested with EAR1 (New England Biolabs, 
Beverly, Massachusetts, USA), which recognizes the base change C/T at promotor 
position -69 in the hGSTA1∗B allele. The digestion was performed on the PCR 
reaction products in a 20 µl reaction using 4 U of restriction enzyme Ear1, 2 µL of 
10X Buffer and 18 µl PCR product for 5 h at 37◦ C. No template control was included. 
The digested products were resolved in a 4 % ultrapure agarose gel post-stained with 
20 µL ethidium bromide for 10 min. The GST1A1*A genotype produced only a band 
at 480 bp. A heterozygote GST1A1*A/B resulted in three bands at 480, 380 and 100 
bp and the GST1A1*B genotype in two bands at 380 and 100 bp. 
UGT1A1 genotyping by microsatellite fragment analysis 
First, PCR was performed using one unlabelled and one, at the 5'-end 6-FAM 
labelled primers (forward primer: 5’-156-FAM/AAGTGAACTCCCTGCTACCTT-3’, 
reverse primer 5’-CCACTGGGATCAACAGTATCT-3’) resulting in a 253 bp PCR 
product, flanking the polymorphic TA locus in the promoter region. Briefly, 80 ng of 
gDNA was amplified with 4 µL of GoTag® Flexi buffer (Promega), 2.5 mM MgCl2, 0.2 
mM each dNTP, 0.1 µM of each UGT1A1 primer. 1 U Taq polymerase was added to 
receive a total reaction volume of 20 µL. Amplification was performed on a VeritiTM 
96-well Thermal Cycler (Applied Biosystems) with an initial denaturation of 94 °C for 
15 min, followed by 30 cycles of 95 °C for 30 s, 58 °C for 40 s and 72 °C for 40 s, 
followed by a final extension of 72 °C for 7 min. Following amplification, PCR 
products were electrophoresed on 2% agarose gels stained with ethidium bromide for 
30 min at 80 V. A no template control was included to detect possible contamination 
issues. 0.5 µL of PCR product were administered to 0.25 µL 1:10 diluted 
GeneScan™ 500 LIZ Size Standard (Applied Biosystems) and 9.25 µL of HiDi 
formamide (Applied Biosystems). Samples were diluted 1:5, subjected to sequencing 
on the 3130 genetic analyzer (Applied Biosystems) for (TA)n, and scored via Gene 
Mapper v4.0 software (Applied Biosystems). Control DNAs from previously 
sequenced individuals known to have a 6/6, 6/7, or 7/7 genotype were included in the 
PCR analysis. The amplified product yielded a 93-or a 95-base pair fragment, which 
corresponded to (TA)6 and (TA)7, respectively. 
Gene transcription by Q-PCR 
At each of the four different blood collection (BC) points, marking the beginning and 
the end of the three different periods of the intervention trial venous blood samples 
were collected in EDTA-tubes and stored at room temperature until the individual 
sampling period was completed. Thereafter, isolation of human peripheral blood 
lymphocytes (PBL), RNA extraction and Q-PCR were performed as previously 
reported [15]. Total RNA was extracted from isolated PBLs following the 
manufactures handbook of the RNeasy®Mini Kit (QIAGEN, Hilden, Germany). 
Following this, 2 µg RNA was reverse-transcribed using Oligo-dT primers and the 
Omniscript® Reverse Transcription Kit (QIAGEN, Hilden, Germany). cDNA obtained 
from the RT reaction (amount corresponding to 2 µg of total RNA) was subjected to 
Q-PCR using QuantiTect SYBR® Green PCR (QIAGEN, Hilden, Germany). The 
primer assays used for the NF2L2 gene was: Hs_NFE2L2_1_SG, QT00027384. ß-
Actin: Hs_ACTB_1_SG, QT00095431 GST1A1: Hs_GST1A1_1_SG, QT00060739. 
GSTT1: Hs_GSTT1_2_SG, QT010751638. UGT1A1: Hs_UGT1A1_1_SG, 
QT00020860 (QIAGEN, Hilden, Germany). Primer concentrations and Q-PCR 
reaction parameters were according to manufacturer's guidelines in QuantiTect 
SYBR® Green PCR Handbook 11/2005 (QIAGEN, Hilden, Germany). Each sample 
was determined in duplicate. A -RT control was included for all assays. The fold 
changes in expression of the target gene relative to the internal control gene (ß-actin) 
was analyzed using Bio-Opticon Software and the CT data was imported into 
Microsoft Excel 03. Data of all assays was analyzed by the 2−ΔΔCT method. 
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Figure 2A 
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Figure Legends 
Figure 1 
(A) Modulation of Nrf2 gene transcription in PBLs of 49 participants of the 
intervention trial (samples of two participants failed to show sufficient fluorescence 
signals/ amplification). The data, analyzed in triplicates are presented as BOX-
diagrams, normalized to ß-actin expression and as relative transcription of individual 
levels of each participant before the study (BC1), after four week wash out 
(polyphenol-poor diet and no coffee consumption, BC2), after four weeks of daily 750 
mL coffee consumption (BC3), after a second wash-out period of four weeks (BC4). 
The data are represented as relative transcription of BC2=1. BC: blood collection. (B) 
Nr2 genotype dependent magnitude of changes in Nrf2 gene transcription during the 
course of the trial. The data are the mean ± SD of the individuals, carrying the 
respective genotype and presented as relative transcription of BC2 (wash out) =1. 
Significances indicated are calculated by Student’s t test (#p < 0.05 and ***, ###p < 
0.001). BC: blood collection. 
 
 
Figure 2 
(A) Modulation of the GST1A1 gene transcription in PBLs of 48 participants of the 
intervention trial (samples of three participants failed to show sufficient fluorescence 
signals/ amplification). The data, performed in triplicates are presented as BOX-
diagrams, normalized to ß-actin expression and as relative transcription of individual 
levels of each participant before the study (BC1), after four week wash-out 
(polyphenol-poor diet and no coffee consumption, BC2), after four weeks of daily 750 
mL coffee consumption (BC3), after a second wash-out period of four weeks (BC4). 
The data are represented as relative transcription of BC2=1. BC: blood collection. (B) 
Nrf2 genotype dependent magnitude of changes in GST1A1 gene transcription 
during the course of the HSG trial. The data are the mean ± SD of the individuals, 
carrying the respective genotype and presented as relative transcription of BC2 
(wash out) =1. Significances indicated are calculated by Student’s t test (*, #p < 0.05 
and ***, ###p < 0.001). BC: blood collection. 
 
 
Figure 3 
(A) Modulation of the UGT1A1 gene transcription in PBLs of 46 participants of the 
HSG trial (samples of five participants failed to show sufficient fluorescence signals/ 
amplification). The data, performed in triplicates are presented as BOX-diagrams, 
normalized to ß-actin expression and as relative transcription of individual levels of 
each participant before the study (BC1), after four week wash-out (polyphenol-poor 
diet and no coffee consumption, BC2), after four weeks of daily 750 mL coffee 
consumption (BC3), after a second wash-out period of four weeks (BC4). The data 
are represented as relative transcription of BC2=1. BC: blood collection. (B) UGT1A1 
genotype dependent magnitude of changes in UGT1A1 gene transcription during the 
course of the HSG trial. The data are the mean ± SD of the individuals, carrying the 
respective genotype and presented as relative transcription of BC2 (wash out) =1. 
(C) Nrf2 genotype dependent magnitude of changes in UGT1A1 gene transcription 
during the course of the HSG trial. The data are the mean ± SD of the individuals, 
carrying the respective genotype and presented as relative transcription of BC2 
(wash out) =1. Significances indicated are calculated by Student’s t test (*, #p < 0.05, 
**p < 0.01 and ***, ###p < 0.001). BC: blood collection. 
 
Table 1 
Gene SNP  Frequency  Literature   
   n [%] n [%]  
Nrf2 -617C/C (WT) 39/49 80 16/20 80 [17] 
 -617C/A 10/49 20 4/20 20 [17] 
 -651G/G (WT) 34/49 69 18/20 90 [17] 
 -651G/A 15/49 31 2/20 10 [17] 
 -653A/A (WT) 18/49 37 15/20 75 [17] 
 -653A/G 31/49 63 5/20 25 [17] 
GST1A1 A/A (WT) 24/48 50 106/27 38 [20] 
 A/B 18/48 38 133/27 48 [20] 
 B/B 6/48 12 39/278 14 [20] 
UGT1A1 [TA]6TAA (WT) 21/46 46 183/399 46 [23] 
 [TA]6/7TAA 19/46 41 169/399 42 [23] 
 [TA]7TAA 6/46 13 47/399 12 [23] 
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